2 “We are pleased to report the first clinical data for RMC-9805, our novel, oral RAS(ON) G12D-selective covalent inhibitor, which demonstrate encouraging initial safety, tolerability and antitumor activity evidenced by tumor regressions,” Mark A. Goldsmi...
2. https://www.targetedonc.com/view/rmc-9805-hits-milestone-in-early-phase-clinical-trial-of-kras-g12d-solid-tumors
Trial Name:Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors ClinicalTrials.gov Identifier:NCT06040541 Sponsor:Revolution Medicines, Inc. Recruitment Contact:650) 779-2300, CT-inquiries@RevMed.com ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of R...
请在备注中输入口令:09274 参考来源: https://www.targetedonc.com/view/rmc-9805-hits-milestone-in-early-phase-clinical-trial-of-kras-g12d-solid-tumors